Modern ideas about the sclerosing lichen of the vulva

Cover Page

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Lichen sclerosus (LS) is a chronic inflammatory disease that is 6-10 times more common in women than in men. The drug affects between 1 in 1000 and 1 in 300 people in the general population, but the exact prevalence is unknown due to the fact that the disease is often asymptomatic. The article presents modern ideas about lichen sclerosus. Issues of various etiological theories of origin and pathogenesis are considered. The description of the clinical picture of lichen sclerosus is given. Diagnostic approaches are described, including the histological picture. Possible complications, including anatomical abnormalities of the vulvar architectonics and the risk of malignant transformation, are discussed in detail. Various methods of treatment and care for this disease, local treatment schemes are presented, an overview of systemic drugs and surgical operations, as well as further observation and management of patients is given.

Full Text

Restricted Access

About the authors

Sergey I. Surkichin

Central State Medical Academy of Department of Presidential Affairs

Author for correspondence.
ORCID iD: 0000-0003-0521-0333

Cand. Sci. (Med.), Associate Professor

Russian Federation, 19 Marshala Timoshenko str., Moscow, 121359

Larisa S. Kruglova

Central State Medical Academy of Department of Presidential Affairs

ORCID iD: 0000-0002-5044-5265
SPIN-code: 1107-4372

Dr. Sci. (Med.)

Russian Federation, 19 Marshala Timoshenko str., Moscow, 121359

Inna A. Apolikhina

Research Center for Obstetrics, Gynecology and Perinatology

ORCID iD: 0000-0002-4581-6295
SPIN-code: 6282-7435

Dr. Sci. (Med.), Professor

Russian Federation, 19 Marshala Timoshenko str., Moscow, 121359

Roman Yu. Mayorov

Central State Medical Academy of Department of Presidential Affairs

ORCID iD: 0000-0003-1911-6743


Russian Federation, 19 Marshala Timoshenko str., Moscow, 121359

Marika Avin

Medical center “Stolitsa”

ORCID iD: 0000-0002-8317-0800


Russian Federation, 19 Marshala Timoshenko str., Moscow, 121359


  1. Powell JJ, Wojnarowska F. Lichen sclerosus. Lancet. 1999;353(9166):1777–1783. doi: 10.1016/s0140-6736(98)08228-2
  2. Birenbaum DL, Young RC. High prevalence of thyroid disease in patients with lichen sclerosus. J Reprod Med. 2007;52(1):28–30
  3. Bercaw-Pratt JL, Boardman LA, Simms-Cendan JS. North American Society for Pediatric and Adolescent Gynecology. Clinical recommendation: pediatric lichen sclerosus. J Pediatr Adolesc Gynecol. 2014;27(2):111–116. doi: 10.1016/j.jpag.2013.11.004
  4. Eisendle K. Possible role of Borrelia burgdorferi sensu lato infection in lichen sclerosus. Arch Dermatol. 2008;144(5):591–598. doi: 10.1001/archderm.144.5.591
  5. Powell J, Strauss S, Gray J, Wojnarowska F. Genital carriage of human papilloma virus (HPV) DNA in prepubertal girls with and without vulval disease. Pediatr Dermatol. 2003;20(3):191–194. doi: 10.1046/j.1525-1470.2003.20301.x
  6. Bunker C, Shim T. Male genital lichen sclerosus. Indian J Dermatol. 2015;60(2):111–117. doi: 10.4103/0019-5154.152501
  7. Oyama N, Chan I, Neill SM, et al. Development of antigen-specific ELISA for circulating autoantibodies to extracellular matrix protein 1 in lichen sclerosus. J Clin Invest. 2004;113(11):1550–1559. doi: 10.1172/JCI20373
  8. Howard A, Dean D, Cooper S, et al. Circulating basement membrane zone antibodies are found in lichen sclerosus of the vulva. Australas J Dermatol. 2004;45(1):12–15. doi: 10.1111/j.1440-0960.2004.00026.x
  9. Strittmatter HJ, Hengge UR, Blecken SR. Calcineurin antagonists in vulvar lichen sclerosus. Arch Gynecol Obstet. 2006;274(5):266–270. doi: 10.1007/s00404-006-0151-1
  10. Kreuter A, Kryvosheyeva Y, Terras S, et al. Association of autoimmune diseases with lichen sclerosus in 532 male and female patients. Acta Derm Venereol. 2013;93(2):238–241. doi: 10.2340/00015555-1512
  11. Goldstein AT, Marinoff SC, Christopher K, Srodon M. Prevalence of vulvar lichen sclerosus in a general gynecology practice. J Reprod Med. 2005;50(7):477–480.
  12. Pérez-López FR, Vieira-Baptista P. Lichen sclerosus in women: a review. Climacteric. 2017;20(4):339–347. doi: 10.1080/13697137.2017.1343295
  13. Fistarol SK, Itin PH. Diagnosis and treatment of lichen sclerosus: an update. Am J Clin Dermatol. 2013;14(1):27–47. doi: 10.1007/s40257-012-0006-4
  14. Flynn AN, King M, Rieff M, et al. Patient satisfaction of surgical treatment of clitoral phimosis and labial adhesions caused by lichen sclerosus. Sex Med. 2015;3(4):251–255. doi: 10.1002/sm2.90
  15. Halonen P, Jakobsson M, Heikinheimo O, et al. Lichen sclerosus and risk of cancer. Int J Cancer. 2017;140(9):1998–2002. doi: 10.1002/ijc.30621
  16. Van de Nieuwenhof HP, van der Avoort IA, de Hullu JA. Review of squamous premalignant vulvar lesions. Crit Rev Oncol Hematol. 2008;68(2):131–156. doi: 10.1016/j.critrevonc.2008.02.012
  17. Bornstein J, Bogliatto F, Haefner HK, et al. The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) terminology of vulvar squamous intraepithelial lesions. J Low Genit Tract Dis. 2016;20(1):11–14. doi: 10.1097/LGT.0000000000000169
  18. Leeker MC, Visser PJ, Overbeek LI, et al. Lichen sclerosus: incidence and risk of vulvar squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2016;25(8):1224–30. doi: 10.1158/1055-9965.EPI-16-0019
  19. La SM, Meli MC, De Pasquale R, et al. Vulvar melanoma associated with lichen sclerosus in a child: case report and literature review. Pediatr Dermatol. 2016;33(3):e190–194. doi: 10.1111/pde.12838
  20. Kirtschig G, Becker K. Evidence-based (S3) Guideline on (anogenital) Lichen sclerosus. JEADV. 2015;29(10):e1–e43. doi: 10.1111/jdv.13136
  21. Virgili A, Minghetti S, Borghi A, Corazza M. Long-term maintenance therapy for vulvar lichen sclerosus: the results of a randomized study comparing topical vitamin E with an emollient. Eur J Dermatol. 2013;23(2):189–194. doi: 10.1684/ejd.2013.1987
  22. Cooper SM, Gao XH, Powell JJ, Wojnarowska F. Does treatment of vulvar lichen sclerosus influence its prognosis? Arch Dermatol. 2004;140(6):702–706. doi: 10.1001/archderm.140.6.702
  23. Brodrick B, Belkin ZR, Goldstein AT. Influence of treatments on prognosis for vulvar lichen sclerosus: facts and controversies. Clin Dermatol. 2013;31(6):780–786. doi: 10.1016/j.clindermatol.2013.05.017
  24. Lewis FM, Tatnall FM, Velangi SS, et al. British Association of Dermatologists guidelines for the management of lichen sclerosus 2018. Br J Dermatol. 2018;178(4):839–853. doi: 10.1111/bjd.16241
  25. Lagos BR, Maibach HI. Frequency of application of topical corticosteroids: an overview. Br J Dermatol. 1998;139(5):763–766. doi: 10.1046/j.1365-2133.1998.02498.x
  26. Funaro D, Lovett A, Leroux N, Powell J. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2014;71(1):84–91. doi: 10.1016/j.jaad.2014.02.019
  27. Wolf B, Horn LC, Hockel M. Anogenital lichen sclerosus: change of tissue position as pathogenetic factor. Gynecol Oncol Rep. 2017;20:73–74. doi: 10.1016/j.gore.2017.03.003
  28. Kirtschig G. Lichen sclerosus-presentation, diagnosis and management. Dtsch Arztebl Int. 2016;113(19):337–343. doi: 10.3238/arztebl.2016.0337



Abstract: 79

PDF (Russian): 1


Article Metrics

Metrics Loading ...


Copyright (c) 2021 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies